Mapping of the Outcome Measures in Rheumatology Core Set for Antineutrophil Cytoplasmic Antibody‐Associated Vasculitis to the International Classification of Function, Disability and Health

Publisher： John Wiley & Sons Inc

E-ISSN： 2151-4658|67|2|255-263

ISSN： 2151-464x

Source： ARTHRITIS CARE AND RESEARCH, Vol.67, Iss.2, 2015-02, pp. : 255-263

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Outcome and Prognosis of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Japan

By  

Nephron Clin Pract, Vol. 115, Iss. 1, 2010-02 ,pp. : c21-c27

Karger

Access to resources Recommend Favorite

Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 11, 2014-11 ,pp. : 3151-3159

John Wiley & Sons Inc

Access to resources Recommend Favorite

Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 2, 2015-02 ,pp. : 535-544

John Wiley & Sons Inc

Access to resources Recommend Favorite

Influenza vaccination and anti‐neutrophil cytoplasmic antibody‐associated vasculitis

By  

NEPHROLOGY, Vol. 20, Iss. 7, 2015-07 ,pp. : 511-512

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: The Road Traveled: Genomics and Biomarkers in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 7, 2015-07 ,pp. : 1700-1702

John Wiley & Sons Inc

Access to resources Recommend Favorite